---
title: "Taltz (ixekizumab) in plaque psoriasis: Clinical trials questions"
description: "Clinical trials questions on Taltz (ixekizumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Itch relief, Maintenance of response, Long-term results, Subgroup results, and Pediatric efficacy. Questions: How effective is Taltz for plaque psoriasis at Week 12 (UNCOVER trials)? How fast does Taltz improve plaque psoriasis (UNCOVER-3)? Does Taltz relieve psoriasis itch at Week 12? Does Taltz maintain clear or almost clear skin through Week 60 (UNCOVER-1 and -2)? 7 further questions follow. 11 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Taltz (ixekizumab) in plaque psoriasis: Clinical trials questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Taltz](https://uspl.lilly.com/taltz/taltz.html#pi)

Questions that apply to every indication of Taltz are on [Taltz (ixekizumab), all indications](https://www.evicenter.com/medical-information/taltz).

## Study results

<a id="taltz-uncover-week-12"></a>

### How effective is Taltz for plaque psoriasis at Week 12 (UNCOVER trials)?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Three multicenter, randomized, double-blind, placebo-controlled trials, Trials 1, 2, and 3 (NCT 01474512, NCT 01597245, NCT 01646177), enrolled a total of 3866 subjects 18 years of age and older with plaque psoriasis who had a minimum body surface area involvement of 10%, a static Physician Global Assessment (sPGA) score of ≥3 in the overall assessment (plaque thickness/induration, erythema, and scaling) of psoriasis on a severity scale of 0 to 5, a Psoriasis Area and Severity Index (PASI) score ≥12, and who were candidates for phototherapy or systemic therapy.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Three%20multicenter%2C%20randomized%2C%20double%2Dblind%2C%20placebo%2Dcontrolled,for%20phototherapy%20or%20systemic%20therapy.)

> “In all three trials, subjects were randomized to either placebo or TALTZ (80 mg every 2 weeks [Q2W]) for 12 weeks, following a 160 mg starting dose.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=In%20all%20three%20trials%2C%20subjects,a%20160%20mg%20starting%20dose.)

> “All three trials assessed the changes from baseline to Week 12 in the two co-primary endpoints: 1) PASI 75, the proportion of subjects who achieved at least a 75% reduction in the PASI composite score that takes into consideration both the percentage of body surface area affected and the nature and severity of psoriatic changes (induration, erythema and scaling) within the affected regions, and 2) sPGA of “0” (clear) or “1” (minimal), the proportion of subjects with an sPGA 0 or 1 and at least a 2-point improvement.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=All%20three%20trials%20assessed%20the,at%20least%20a%202%2Dpoint%20improvement.)

> “Table 3: Efficacy Results at Week 12 in Adults with Plaque Psoriasis in Trials 1, 2, and 3; NRIa
>
> a Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-Responder Imputation.
>
>
>
>
> b At Week 0, subjects received 160 mg of TALTZ.
>
>
>
>
> c Co-primary endpoints.
>
>
>
>
> d Itch NRS (≥4 improvement) in subjects with baseline Itch NRS ≥4. The number of ITT subjects with baseline Itch NRS Score ≥4 are as follows: Trial 1, TALTZ n=391, PBO n=374; Trial 2, TALTZ n=303, PBO n=135; Trial 3, TALTZ n=320, PBO n=158.
>
>
> 	Trial 1	Trial 2	Trial 3
> TALTZ 80 mgb
> Q2W (N=433)
> n (%)	Placebo
> (N=431)
> n (%)	TALTZ 80 mgb
> Q2W (N=351)
> n (%)	Placebo
> (N=168)
> n (%)	TALTZ 80 mgb
> Q2W (N=385)
> n (%)	Placebo
> (N=193)
> n (%)
> sPGA of “0” (clear) or “1” (minimal)c	354 (82)	14 (3)	292 (83)	4 (2)	310 (81)	13 (7)
> sPGA of “0” (clear)	160 (37)	0	147 (42)	1 (1)	155 (40)	0
> PASI 75c	386 (89)	17 (4)	315 (90)	4 (2)	336 (87)	14 (7)
> PASI 90	307 (71)	2 (1)	248 (71)	1 (1)	262 (68)	6 (3)
> PASI 100	153 (35)	0	142 (40)	1 (1)	145 (38)	0
> Itch NRS (≥4 point improvement)d	336 (86)	58 (16)	258 (85)	19 (14)	264 (83)	33 (21)”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Table%203%3A%20Efficacy%20Results%20at,33%20%2821%29)

> “In an NRI analysis of UNCOVER-1 (Taltz n=433; placebo n=431), UNCOVER-2 (Taltz n=351; placebo n=168), and UNCOVER-3 (Taltz n=385; placebo n=193), at week 12, 89%, 90% and 87% of patients receiving Taltz, respectively, achieved PASI 75 vs 4%, 2%, and 7% for placebo, respectively; 71%, 71% and 68% of patients receiving Taltz, respectively, achieved PASI 90 vs 1%, 1%, and 3% for placebo, respectively; 35%, 40% and 38% of patients receiving Taltz, respectively, achieved PASI 100 vs 0%, 1%, and 0% for placebo, respectively.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=In%20an%20NRI%20analysis%20of,and%200%25%20for%20placebo%2C%20respectively.)

> “In UNCOVER-1, -2, and -3, 82%, 83%, and 81% of Taltz patients, respectively, achieved sPGA 0,1 at 12 weeks vs 3%, 2%, and 7% for placebo.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=In%20UNCOVER%2D1%2C%20%2D2%2C%20and%20%2D3%2C,2%25%2C%20and%207%25%20for%20placebo.)

Note: The Prescribing Information calls these trials Trials 1, 2, and 3; the Taltz HCP site calls them UNCOVER-1, -2, and -3. Table 3 columns are TALTZ 80 mg Q2W and placebo for Trial 1, Trial 2, and Trial 3, in that order. Trials 2 and 3 also had an etanercept arm, which this answer does not include.

<a id="taltz-uncover-3-speed"></a>

### How fast does Taltz improve plaque psoriasis (UNCOVER-3)?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “In an observed analysis of UNCOVER-3 (Taltz n=385; placebo n=193), at weeks 2, 4, 8, and 12 (the induction period), patients receiving Taltz achieved mean percentage improvement in PASI from baseline of 56%, 74%, 86%, and 92%, respectively, vs 11%, 13%, 15%, and 14% for placebo, respectively. Additionally, at weeks 36, 48, 60, 108, 156, 204, and 264 (the open-label extension period), patients receiving Taltz achieved 95%, 95%, 96%, 95%, 96%, 97% and 97% of mean percentage improvement in PASI from baseline, respectively.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=In%20an%20observed%20analysis%20of%20UNCOVER%2D3%20%28Taltz%20n%3D385%3B,in%20PASI%20from%20baseline%2C%20respectively.)

> “This was a post hoc observed analysis of intent-to-treat population through week 264.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=This%20was%20a%20post%20hoc,intent%2Dto%2Dtreat%20population%20through%20week%20264.)

> “The open-label extension phase of the study has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=The%20open%2Dlabel%20extension%20phase%20of,be%20those%20with%20better%20results%29.)

## Itch relief

<a id="taltz-itch"></a>

### Does Taltz relieve psoriasis itch at Week 12?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Other evaluated outcomes included the proportion of subjects with an sPGA score of 0 (clear), a reduction of at least 90% in PASI (PASI 90), a reduction of 100% in PASI (PASI 100), and an improvement of itch severity as measured by a reduction of at least 4 points on an 11-point itch Numeric Rating Scale.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Other%20evaluated%20outcomes%20included%20the,11%2Dpoint%20itch%20Numeric%20Rating%20Scale.)

> “Itch NRS (≥4 point improvement)d	336 (86)	58 (16)	258 (85)	19 (14)	264 (83)	33 (21)”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Itch%20NRS%20%28%E2%89%A54%20point%20improvement%29d,33%20%2821%29)

> “d Itch NRS (≥4 improvement) in subjects with baseline Itch NRS ≥4. The number of ITT subjects with baseline Itch NRS Score ≥4 are as follows: Trial 1, TALTZ n=391, PBO n=374; Trial 2, TALTZ n=303, PBO n=135; Trial 3, TALTZ n=320, PBO n=158.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=d%20Itch%20NRS%20%28%E2%89%A54%20improvement%29,3%2C%20TALTZ%20n%3D320%2C%20PBO%20n%3D158.)

Note: The row is from Table 3 of the Prescribing Information (Week 12, non-responder imputation). Its columns are TALTZ 80 mg Q2W and placebo for Trial 1, Trial 2, and Trial 3, in that order, as n (%).

## Maintenance of response

<a id="taltz-maintenance-week-60"></a>

### Does Taltz maintain clear or almost clear skin through Week 60 (UNCOVER-1 and -2)?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “To evaluate the maintenance and durability of response, subjects originally randomized to TALTZ and who were responders at Week 12 (i.e., sPGA of 0 or 1) in Trial 1 and Trial 2 were re-randomized to an additional 48 weeks of either a maintenance dose of TALTZ 80 mg Q4W (every 4 weeks) or placebo. Non-responders (sPGA >1) at Week 12 and subjects who relapsed (sPGA ≥3) during the maintenance period were placed on TALTZ 80 mg Q4W.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=To%20evaluate%20the%20maintenance%20and,on%20TALTZ%2080%20mg%20Q4W.)

> “For responders at Week 12, the percentage of subjects who maintained this response (sPGA 0 or 1) at Week 60 (48 weeks following re-randomization) in the integrated trials (Trial 1 and Trial 2) was higher for subjects treated with TALTZ 80 mg Q4W (75%) compared to those treated with placebo (7%).”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=For%20responders%20at%20Week%2012%2C,those%20treated%20with%20placebo%20%287%25%29.)

> “In the maintenance period of UNCOVER-1 & -2, 75% of the patients receiving Taltz every 4 weeks who achieved sPGA 0,1 at week 12, maintained that response at week 60 (n=181*) compared with 7% of patients receiving placebo (n=203<sup>*</sup>) (NRI).”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=In%20the%20maintenance%20period%20of,%28NRI%29.)

> “<sup>*</sup>Evaluable patients at week 60.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=patients%20at%20week%2060.)

<a id="taltz-stopping-treatment"></a>

### What happens when Taltz is stopped after psoriasis clears?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “For responders at Week 12 who were re-randomized to treatment withdrawal (i.e., placebo), the median time to relapse (sPGA ≥3) was 164 days in the integrated trials. Among these subjects, 66% regained a response of at least 0 or 1 on the sPGA within 12 weeks of restarting treatment with TALTZ 80 mg Q4W.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=For%20responders%20at%20Week%2012%20who,with%20TALTZ%2080%20mg%20Q4W.)

## Long-term results

<a id="taltz-five-year-results"></a>

### Does Taltz keep working for psoriasis through 5 years (UNCOVER-3)?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “In an observed analysis of UNCOVER-3 (Taltz N=385), at week 12, 72% of patients achieved PASI 90, and 40% of patients achieved PASI 100. Additionally, at weeks 60, 108, 156, 204, and 264, 84%, 81%, 87%, 88%, and 90% of patients, respectively, achieved PASI 90; and 64%, 58%, 65%, 67%, and 66% of patients, respectively, achieved PASI 100.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=In%20an%20observed%20analysis%20of,patients%2C%20respectively%2C%20achieved%20PASI%20100.)

> “In an mNRI analysis of UNCOVER-3, at week 12, 70% of patients achieved PASI 90, and 39% of patients achieved PASI 100. Additionally, at weeks 60, 108, 156, 204, and 264, 78%, 71%, 69%, 66%, and 67% of patients, respectively, achieved PASI 90; and 59%, 50%, 49%, 48%, and 46% of patients, respectively, achieved PASI 100.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=In%20an%20mNRI%20analysis%20of,patients%2C%20respectively%2C%20achieved%20PASI%20100.)

> “These were post hoc analyses of ITT population through week 264.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=These%20were%20post%20hoc%20analyses%20of%20ITT%20population%20through%20week%20264.)

> “A subset of patients from UNCOVER-3 who received a 160 mg starting dose of Taltz at week 0, followed by 80 mg every 2 weeks through week 12, followed by 80 mg every 4 weeks, is shown.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=A%20subset%20of%20patients%20from,every%204%20weeks%2C%20is%20shown.)

> “The open-label phase of the study beginning after week 12 has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=The%20open%2Dlabel%20phase%20of%20the,be%20those%20with%20better%20results%29.)

## Subgroup results

<a id="taltz-scalp-psoriasis"></a>

### Does Taltz work for scalp psoriasis?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “In the post hoc mNRI analysis of UNCOVER-3 study, among patients with scalp psoriasis (Taltz n=349; placebo n=176), patients receiving Taltz at weeks 12 (the induction period), 60, 108, 156, 204, and 264 (the open-label extension period), 78%, 81%, 78%, 74%, 64%, and 69% of patients, respectively, achieved PSSI=0; at week 12, 10% of patients on placebo achieved PSSI=0.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=In%20the%20post%20hoc%20mNRI,patients%20on%20placebo%20achieved%20PSSI%3D0.)

On the page, select: Scalp data (PSSI 0)

> “PSSI=0 response rates are for a subset of patients from UNCOVER-3 with baseline scalp psoriasis. The mean baseline PSSI score was 20 for Taltz.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=PSSI%3D0%20response%20rates%20are%20for,score%20was%2020%20for%20Taltz.)

On the page, select: Scalp data (PSSI 0)

> “The open-label phase of the study has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=The%20open%2Dlabel%20phase%20of%20the%20study%20has,be%20those%20with%20better%20results%29.)

On the page, select: Scalp data (PSSI 0)

<a id="taltz-nail-psoriasis"></a>

### Does Taltz work for nail psoriasis?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “In the post hoc mNRI analysis of UNCOVER-3 study, among patients with nail psoriasis (Taltz n=229; placebo n=116), patients receiving Taltz at weeks 12 (the induction period), 60, 108, 156, 204, and 264 (the open-label extension period), 18%, 65%, 65%, 70%, 60%, and 64% of patients, respectively, achieved NAPSI=0; at week 12, 4% of patients on placebo achieved NAPSI=0.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=In%20the%20post%20hoc%20mNRI,patients%20on%20placebo%20achieved%20NAPSI%3D0.)

> “NAPSI=0 response rates were for a subset of patients from UNCOVER-3 with baseline nail psoriasis. For nail psoriasis assessments, only fingernail psoriasis was assessed in UNCOVER-3. The mean baseline NAPSI score was 27 for Taltz.<sup>1,2</sup>”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=NAPSI%3D0%20response%20rates%20were%20for,NAPSI%20score%20was%2027%20for)

> “The open-label phase of the study has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=The%20open%2Dlabel%20phase%20of%20the%20study%20has,be%20those%20with%20better%20results%29.)

<a id="taltz-palmoplantar-psoriasis"></a>

### Does Taltz work for palmoplantar (hand and foot) psoriasis?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “In the post hoc mNRI analysis of UNCOVER-3 study, among patients with palmoplantar psoriasis (Taltz n=96; placebo n=54), patients receiving Taltz at weeks 12 (the induction period), 60, 108, 156, 204, and 264 (the open-label extension period), 65%, 78%, 79%, 72%, 78%, and 75% of patients, respectively, achieved PPASI 100; at week 12, 30% of patients on placebo achieved PPASI 100.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=In%20the%20post%20hoc%20mNRI%20analysis%20of%20UNCOVER%2D3%20study%2C%20among%20patients%20with,-palmoplantar%20psoriasis%20%28Taltz)

> “PPASI 100 response rates are for a subset of patients from UNCOVER-3 with baseline non-pustular palmoplantar psoriasis. The mean baseline PPASI score was 10 for Taltz.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=PPASI%20100%20response%20rates%20are,score%20was%2010%20for%20Taltz.)

> “The open-label phase of the study has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=10%20for%20Taltz.-,The%20open%2Dlabel%20phase%20of%20the%20study%20has%20limitations%20%28eg%2C%20no,be%20those%20with%20better%20results%29.)

<a id="taltz-genital-psoriasis"></a>

### How effective is Taltz for genital psoriasis?

Applies to: Adults with plaque psoriasis involving the genital area

> “A randomized, double-blind, placebo-controlled trial (Trial 4) was conducted in 149 adult subjects with plaque psoriasis who had a minimum body surface area (BSA) involvement of 1%, a sPGA score of ≥3 (moderate psoriasis), a sPGA of Genitalia score of ≥3 (moderate psoriasis involving the genital area), who failed to respond to or were intolerant of at least one topical therapy used for treatment of psoriasis affecting the genital area, and who were candidates for phototherapy and/or systemic therapy.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=A%20randomized%2C%20double%2Dblind%2C%20placebo%2Dcontrolled%20trial,for%20phototherapy%20and%2For%20systemic%20therapy.)

> “Table 4: Efficacy Results at Week 12 in Adults with Genital Psoriasis in Trial 4; NRIa
>
> a Abbreviations: NRI = Non-Responder Imputation; GPSS = Genital Psoriasis Symptoms Scale; GenPs-SFQ = Genital Psoriasis Sexual Frequency Questionnaire.
>
>
>
>
> b At Week 0, subjects received 160 mg of TALTZ, followed by 80 mg every 2 weeks for 12 weeks.
>
>
> Endpoints	TALTZ 80 mg Q2Wb
> n (%)	Placebo
> n (%)
> Number of subjects randomized	N=75	N=74
>        sPGA of Genitalia “0” (clear) or “1” (minimal)	55 (73%)	6 (8%)
>        sPGA “0” (clear) or “1” (minimal)	55 (73%)	2 (3%)
> Number of subjects with baseline GPSSa Itch NRS Score ≥4	N=56	N=51
>        GPSS Genital Itch (≥4 point improvement)	31 (55%)	3 (6%)
> Number of subjects with baseline GenPs-SFQa Item 2 Score ≥2	N=37	N=42
>        GenPs-SFQ Item 2 score “0” (never) or “1” (rarely)	29 (78%)	9 (21%)”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Table%204%3A%20Efficacy%20Results%20at,9%20%2821%25%29)

> “In the NRI analysis of IXORA-Q study, among patients with genital psoriasis (Taltz n=75; placebo n=74), patients receiving Taltz at week 12 (the induction period), 24, and 52 (the open-label extension period), 56%, 61% and 60% of patients achieved sPGA-G 0 response; at week 12, 5% of patients on placebo achieved sPGA-G 0 response.
>
> NRI of intent-to-treat population through week 52.
>
> In NRI analysis, 73% of Taltz patients achieved sPGA-G 0,1 at week 12 compared to 8% of placebo (primary endpoint).
>
> The open-label phase of the study beginning after week 12 has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).
>
> Data were from a pre-specified, exploratory endpoint and not controlled for type-I error.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=In%20the%20NRI%20analysis%20of,not%20controlled%20for%20type%2DI%20error.)

On the page, select: Genital data (sPGA-G 0)

Note: The first two passages are from the Prescribing Information, which reports Trial 4; the third is from the Taltz HCP site, which reports IXORA-Q. Table 4 columns are TALTZ 80 mg Q2W and placebo.

## Pediatric efficacy

<a id="taltz-pediatric-efficacy"></a>

### How effective is Taltz in children with plaque psoriasis (IXORA-Peds)?

Applies to: Moderate-to-severe plaque psoriasis in pediatric patients 6 to less than 18 years of age

> “A randomized, double-blind, multicenter, placebo-controlled trial (IXORA-Peds, NCT03073200) enrolled 171 pediatric subjects 6 to less than 18 years of age, with moderate-to-severe plaque psoriasis (as defined by a sPGA score ≥3, involving ≥10% of the body surface area, and a PASI score ≥12) who were candidates for phototherapy or systemic therapy or were inadequately controlled on topical therapy.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=A%20randomized%2C%20double%2Dblind%2C%20multicenter%2C%20placebo%2Dcontrolled,inadequately%20controlled%20on%20topical%20therapy.)

> “Table 5: Efficacy Results in Pediatric Subjects with Plaque Psoriasis in IXORA-Peds, NRIa
>
> a Abbreviations: N = Number of subjects in the intent-to-treat population; NRI = Non-Responder Imputation.
>
>
>
>
> b At Week 0, subjects received 160 mg, 80 mg, or 40 mg of TALTZ, followed by 80 mg, 40 mg, or 20 mg every 4 weeks, depending on weight category, for 12 weeks.
>
>
>
>
> c Co-primary endpoints.
>
>
>
>
> d Itch NRS (≥4 improvement) in subjects with baseline Itch NRS ≥4. The number of ITT subjects with baseline Itch NRS Score ≥4 are as follows: TALTZ, n = 83; PBO, n = 40.
>
>
> 	TALTZb
> (N=115)
> n (%)	Placebo
> (N=56)
> n (%)
> Week 12		
>    sPGA “0” (clear) or “1” (minimal)c	93 (81%)	6 (11%)
>    sPGA “0” (clear)	60 (52%)	1 (2%)
>    PASI 75c	102 (89%)	14 (25%)
>    PASI 90	90 (78%)	3 (5%)
>    PASI 100	57 (50%)	1 (2%)
>    Itch NRS (≥4 point improvement)d	59 (71%)	8 (20%)
> Week 4		
>    sPGA “0” (clear) or “1” (minimal)	55 (48%)	4 (7%)
>    PASI 75	62 (54%)	5 (9%)”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Table%205%3A%20Efficacy%20Results%20in,5%20%289%25%29)

> “In an NRI analysis of IXORA-PEDS (Taltz n=115; placebo n=56), at week 12, 89%<sup>*</sup> of patients receiving Taltz achieved PASI 75 vs 25% for placebo; 78%<sup>*</sup> of patients receiving Taltz achieved PASI 90 vs 5% for placebo; and 50%<sup>*</sup> of patients receiving Taltz achieved PASI 100 vs 2% for placebo.”

Source: [TALTZ: Pediatric Psoriasis Treatment Efficacy & Safety, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/pediatric-psoriasis#:~:text=In%20an%20NRI%20analysis%20of,100%20vs%202%25%20for%20placebo.)

> “<sup>*</sup>P<.001 vs placebo at week 12.”

Source: [TALTZ: Pediatric Psoriasis Treatment Efficacy & Safety, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/pediatric-psoriasis#:~:text=vs%20placebo%20at%20week%2012.)

Note: Table 5 columns are TALTZ and placebo, as n (%).

## Related pages
- [Medical information: Taltz (ixekizumab): Plaque psoriasis](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/guidelines)
